Nrx Pharmaceuticals, INC DEF 14A proxy statements

NRx Pharmaceuticals, Inc. filed a supplement to its definitive proxy statement to correct proposal numbering for its upcoming March 23, 2026 annual meeting.

NRx Pharmaceuticals, Inc. announces its 2026 Annual Meeting of Stockholders to address director elections, an equity incentive plan amendment, auditor ratification, and executive compensation.

NRx Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders on October 8, 2024, to vote on key proposals including director elections, share issuance approval, a potential reverse stock split, and auditor ratification.

NRx Pharmaceuticals amends its proxy statement to include information about retaining Alliance Advisors LLC for proxy solicitation at a cost of approximately $50,000 plus expenses.

NRx Pharmaceuticals plans to distribute 49% of HOPE Therapeutics stock and a royalty right of 1% of Ketamine sales to existing NRXP shareholders and applicable warrant holders.

NRx Pharmaceuticals initiates a strategy to combat short selling, including a potential reverse stock split, name change, and engagement with former SEC enforcement leaders.

NRx Pharmaceuticals is asking stockholders to approve a reverse stock split to increase its stock price and maintain its listing on the Nasdaq Capital Market.